Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights financial and strategic challenges, including NASDAQ delisting and funding needs, which overshadow progress in clinical trials. The Q&A reveals uncertainties in business development and data disclosure timelines. Despite some positive regulatory signals, the overall sentiment is negative due to financial instability and execution risks.
Key Financial Performance
NASDAQ Delisting Sangamo's common stock transitioned to trading on the OTCQB Venture Market following a delisting determination from NASDAQ Capital Markets due to noncompliance with NASDAQ's minimum bid requirements. This change reflects challenges in maintaining compliance with NASDAQ's standards.
ST-920 BLA Submission The rolling submission of the BLA for ST-920 in Fabry disease is in progress, with the first two modules submitted. The company anticipates completing the submission by summer, contingent on securing additional funding. This reflects progress in regulatory pathways for the treatment.
Phase I/II STAND Study for ST-503 Six clinical sites have been activated for the Phase I/II STAND study evaluating ST-503 for intractable pain due to small fiber neuropathy. This marks progress in clinical trial activities.
ST-506 for Prion Disease The GLP toxicology study for ST-506 has been completed, and analysis is ongoing. Additionally, alignment with the U.K.'s MHRA on diagnostic testing and safety matters has been achieved, indicating progress in regulatory and clinical trial preparation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ST-920 (Fabry Disease): Rolling submission of BLA to the FDA is in progress, with the first two modules submitted. The FDA has agreed to an accelerated approval pathway using mean annualized eGFR slope at 52 weeks across 32 dosed patients. No additional confirmatory study is required for traditional approval, and 104-week data will be submitted for this purpose.
ST-503 (Small Fiber Neuropathy): Six clinical sites have been activated for the Phase I/II STAND study. A manuscript detailing preclinical safety and pharmacology has been published in Science Translational Medicine.
ST-506 (Prion Disease): Clinical trial application enabling activities are ongoing. A GLP toxicology study has been completed, and analysis is underway. Productive discussions with the U.K.'s MHRA have been held, aligning on diagnostic testing and safety matters.
NASDAQ Delisting and OTCQB Transition: Sangamo's stock transitioned to the OTCQB Venture Market following a delisting determination from NASDAQ due to noncompliance with minimum bid requirements. The company plans to appeal the decision in June while maintaining access to public markets.
Capital Raising and Strategic Options: Sangamo is actively pursuing opportunities to raise additional capital and is supported by a global investment bank. Business development discussions for a potential Fabry commercialization agreement are ongoing.
Gene and Cell Therapy Innovation: Presented advances in zinc finger epigenetic regulation for Nav1.7 and prion disease, as well as Modular Integrase technology, at the ASGCT Annual Meeting. Achieved significant progress in targeted genome integration across various cell types.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
NASDAQ Delisting: Sangamo's common stock was delisted from NASDAQ due to noncompliance with minimum bid requirements, which could impact investor confidence and access to capital.
Funding Challenges: The company’s ability to complete the BLA submission for ST-920 and continue operations is contingent on securing adequate additional funding, posing a risk to its financial stability and project timelines.
Regulatory Approval Dependencies: The progress of ST-920 and other pipeline projects depends on regulatory approvals, which are subject to uncertainties and could delay commercialization.
Market Transition to OTCQB: The transition to the OTCQB Venture Market may limit Sangamo's visibility and liquidity in the public markets, potentially affecting its ability to attract investors.
Strategic Execution Risks: The company is actively pursuing strategic options, including partnerships and commercialization agreements, which carry execution risks and uncertainties.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ST-920 BLA Submission: The rolling submission of the Biologics License Application (BLA) for ST-920, an investigational gene therapy for Fabry disease, is in progress. The first two modules have been submitted, and the company anticipates completing the submission by summer 2026, contingent on securing adequate additional funding. The FDA has agreed to an accelerated approval pathway using mean annualized eGFR slope at 52 weeks across all 32 dosed patients. Traditional approval may be sought with 104-week data, and no additional confirmatory study is required.
Neurology Pipeline - ST-503: Six clinical sites have been activated for the Phase I/II STAND study evaluating ST-503, an investigational epigenetic regulator for intractable pain due to small fiber neuropathy (SFN). Patient identification is ongoing.
Neurology Pipeline - ST-506: Clinical trial application (CTA) enabling activities for ST-506, an epigenetic regulator for prion disease, are advancing. A GLP toxicology study has been completed, and analysis is ongoing. Alignment with the U.K.'s MHRA has been achieved on diagnostic testing, analytical validation, and nonclinical safety matters.
Strategic Financial Position: The company is actively pursuing opportunities to raise additional capital and evaluating strategic options to maximize the value of its assets. A global investment bank is supporting these efforts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you walk us through the gating factors for analyzing the 104-week data set and disclosing it? Would you wait to present the data at a medical conference or disclose it earlier after filing the BLA?
A:The company is 3/5 through the rolling submission, with the clinical module and 1-year data already submitted. They are conducting cleaning processes to gather the full 2-year data and will decide the best time to submit it. They reassured that patients are showing stability out to 5 years, with 4 patients beyond 5 years showing supraphysiological levels of alpha-Gal and remarkable safety. Additionally, 17 patients are off ERT, with some over 3 years off ERT.
Q:How will FDA's recent affirmation that 2-year eGFR data can serve as confirmatory evidence affect your BD discussions? Are there any updates on the BD discussion around the Fabry program?
A:The company cannot discuss BD conversations but noted that the affirmation from the FDA is likely viewed positively by interested parties. The focus is on achieving accelerated approval with 1-year data. The agency's signaling that a second study is unnecessary is significant as it avoids additional costs and delays. The 2-year data is being gathered and shows durability, with plans to share it at the appropriate time.
Q:Review of Unclear Management Responses
A:The management avoided providing direct answers regarding updates on BD discussions around the Fabry program, citing confidentiality. They also did not specify a timeline for disclosing the 2-year data or whether it would be presented at a medical conference or disclosed earlier.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASGCT forum
American Society
Annual WORLD
Boston abstract
CEO afternoon
Cell Therapy
Communications Maam
DNA genome
Gene Cell
Healthcare Products
Integrase technology
MHRA alignment
Maam Head
Market month
Market receipt
Markets noncompliance
Medicine Healthcare
Meeting ASGCT
Modular Integrase
NASDAQ Capital
Nathalie update
OTCQB Venture
Venture Market
afternoon today
determination
market
module
prion disease
site
stock
submission BLA
week patient
SGMO Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call highlights financial and strategic challenges, including NASDAQ delisting and funding needs, which overshadow progress in clinical trials. The Q&A reveals uncertainties in business development and data disclosure timelines. Despite some positive regulatory signals, the overall sentiment is negative due to financial instability and execution risks.
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
SGMO Slides
SGMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
